Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Stomach Neoplasms 5Gastrointestinal Neoplasms 3Pancreatic Neoplasms 2Esophageal Neoplasms 2Rectal Neoplasms 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Colonic Neoplasms 1Bile Duct Neoplasms 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Cisplatin 51Gemcitabine 26toripalimab 20Radiotherapy, Intensity-Modulated 19Fluorouracil 16Capecitabine 16camrelizumab 15Docetaxel 14nimotuzumab 12Radiotherapy 10Drug Therapy 10apatinib 9Nivolumab 9sintilimab 8endostar protein 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Immune Checkpoint Inhibitors 7tislelizumab 6spartalizumab 6Chemoradiotherapy 6Cetuximab 6Bevacizumab 6pembrolizumab 5nedaplatin 5S 1 (combination) 5Radiation 5Paclitaxel 5Endostatins 5anlotinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Nasopharyngeal Carcinoma × tegafur-gimeracil-oteracil × Clear all
NCT03904225 2021-06-23

Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis

Zhejiang Cancer Hospital

Phase 2 Unknown
220 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡